GlassScriptPhysician profile
Ambuga R Badari
NPI 1851555874
$2,327.95
in general payments reported to CMS, 2019-2025
11 companies · $18.87 in 2025
The $18.87 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.07 · 2020: $1,840 · 2021: $68.03 · 2022: $28.29 · 2023: $143 · 2024: $217 · 2025: $18.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $200 · Education: $99.00 · Food and Beverage: $79.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $200.00 |
| Education | $99.00 |
| Food and Beverage | $79.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,840.00 | 2020 | |
| Sobi, INC | $200.00 | 2024 | |
| Incyte Corporation | $99.00 | 2023 | |
| Beigene USA, INC. | $48.06 | 2021-2023 | Brukinsa |
| Abbvie INC. | $36.02 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $28.29 | 2022 | |
| Merck Sharp & Dohme LLC | $24.67 | 2023 | Lynparza |
| Boston Scientific Corporation | $20.00 | 2021 | |
| Janssen Biotech, INC. | $18.84 | 2021 | |
| Pfizer INC. | $13.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambuga Badari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.